Oral Ulcers in Behçet's Disease

About Behçet’s Disease

Behçet’s Disease (BD) is also referred to as Behçet’s Syndrome1

Click arrow for more information

  • About BD
  • Oral Ulcers in BD
  • Treatment for Oral Ulcers in BD

Behçet’s Disease is a rare, chronic, multisystem inflammatory disorder1

Behçet’s Disease, also referred to as Behçet’s Syndrome, is classified as a variable vessel vasculitis.1

  • Multiple systems can be affected by BD, but it is often characterized by recurrent oral ulcers accompanied by lesions in other organ systems1
  • The International Study Group (ISG) criteria can be used to diagnose BD by the presence of recurrent oral ulceration plus at least 2 of the following: recurrent genital ulceration, eye lesions, skin lesions, or a positive result on pathergy testing2

A diagnosis of BD typically takes approximately 5 years from the onset of manifestations3

Prevalence of manifestations4

Recurrent oral ulcers are the hallmark manifestation of BD5

Oral ulcers can be bothersome and painful6,7

  • Present in 98% of patients diagnosed with BD3,4
  • Recurrent oral ulcers in BD can crop, be painful, and scar4,8
  • Diagnosis of BD with recurrent oral ulcers is complicated by a number of possible differential diagnoses, such as aphthous stomatitis or inflammatory bowel disease, among others9

Oral ulcers can present in 98% of patients with BD3,4

Major-type oral aphthous ulcer10

Oral aphthous ulcer11

Herpetiform ulceration11

Otezla is the first and only FDA-approved systemic therapy for oral ulcers associated with BD12

  • In BD, the efficacy of Otezla® (apremilast) was demonstrated based on the number and pain of oral ulcers
  • The most commonly reported adverse reactions (≥10%) for Otezla were diarrhea, nausea, headache, and upper respiratory tract infection

An oral, non-biologic systemic treatment for patients with oral ulcers associated with Behçet’s Disease12

References: 1. Leonardo NM, McNeil J. Int J Rheumatol. 2015;2015:945262. 2. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078-1080. 3. Alpsoy E, Donmez L, Onder M, et al. Br J Dermatol. 2007;157(5):901-906. 4. Yazici Y, Yazici H, eds. Behçet’s Syndrome. New York, NY: Springer; 2010:7-34. 5. Zeidan MJ, Saadoun D, Garrido M, et al. Autoimmun Highlights. 2016;7(1):4. 6. Alpsoy E. J Dermatol. 2016;43(6):620-632. 7. Melikoglu M, Melikoglu M. Acta Reumatol Port. 2014;39:46-53. 8. Bang D, Hur W, Lee ES, Lee S. J Dermatol. 1995;22(12):926-929. 9. Ambrose NL, Haskard DO. Nat Rev Rheumatol. 2013;9(2):79-89. 10. Lee S, Bang D, Lee ES, Sohn S, eds. Behçet’s Disease: A Guide to its Clinical Understanding Textbook and Atlas. Heidelberg, Germany: Springer-Verlag; 2001:19-50. 11. Gualtierotti R, Marzano AV, Spadari F, et al. J Clin Med. 2019;8(1):1-19; 12. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a Healthcare Professional?

.marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: 44px; text-transform: none; margin-bottom: 10px; } .marketAccessModal .lineTwo { font-size: 42px; text-transform: none; } @media screen and (max-width: 450px) { .marketAccessModal .lineOne, .marketAccessModal .lineTwo { font-size: calc(15px + 7 * ((100vw - 325px) / 125)); } }
The FDA approves a new indication for Otezla® (apremilast) Learn more about this treatment option for your patients